PAD and CLI patients who show signs of coronary heart disease may benefit from early treatment, according to a new study of nearly 4 million hospitalizations.
Relying on the AI-powered chatbot for heart assessments could be "dangerous," researchers warn, but the technology may still be helpful in certain situations.
Interventional cardiologists from all over the world will gather for three days of educational sessions, late-breaking presentations, live cases and more. The festivities begin Thursday, May 2, in Long Beach, California.
STS risk calculators are known as a go-to resource for cardiologists, surgeons and any other healthcare providers who manage the care of heart patients.
The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.
Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."
![An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.](/sites/default/files/styles/stack_views/public/2024-04/screen_shot_2024-04-26_at_10.55.10_am.png.webp?itok=eF1mw-vN)
